Orthogen Overview

  • Founded
  • 1993
  • Status
  • Private
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 1

Orthogen General Information


Developer of advance medical therapies intended to treat orthopedic diseases. The company's therapies are used in developing biological antagonist substances to aid in preventing inflammation of joints and nerve roots, regenerate joint cartilage and accelerate healing of fractures, enabling physicians to treat chronic bone and nerve injuries with high success rates.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Ernst-Schneider-Platz 1
  • 40212 Düsseldorf
  • Germany
+49 0211 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Orthogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC Completed Startup
To view Orthogen’s complete valuation and funding history, request access »

Orthogen Executive Team (4)

Name Title Board Seat Contact Info
Peter Wehling Ph.D Co-Founder & Chief Executive Officer
Julio Reinecke Ph.D Co-Founder, Managing Director & Head, Research & Development
Klaus Wehling Co-Founder
Christopher Evans Ph.D Chairman of Supervisory Board
To view Orthogen’s complete executive team members history, request access »

Orthogen Board Members (1)

Name Representing Role Since
Christopher Evans Ph.D Orthogen Chairman of Supervisory Board 000 0000
To view Orthogen’s complete board members history, request access »

Orthogen Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
QVentures Venture Capital Minority 000 0000 000000 0
To view Orthogen’s complete investors history, request access »